Childhood disintegrative disorder
|Childhood disintegrative disorder|
|Classification and external resources|
|Patient UK||Childhood disintegrative disorder|
The childhood disintegrative disorder (CDD), also known as Heller's syndrome and disintegrative psychosis, is a rare condition characterized by late onset of developmental delays in language, social function, and motor skills. Researchers have not been successful in finding a cause for the disorder. CDD has some similarity to autism, and is sometimes considered a low-functioning form of it.
CDD was originally described by Austrian educator Theodor Heller (1869 – 1938) in 1908, 35 years before Leo Kanner and Hans Asperger described autism. Heller had previously used the name dementia infantilis for the syndrome.
An apparent period of fairly normal development is often noted before a regression in skills or a series of regressions in skills. The age at which this regression can occur varies, but typically after 3 years of normal development. The regression can be so dramatic that the child may be aware of it, and may in its beginning even ask, vocally, what is happening to her/him. Some children describe or appear to be reacting to hallucinations, but the most obvious symptom is that skills apparently attained are lost.
Many children are already somewhat delayed when the disorder becomes apparent, but these delays are not always obvious in young children. This has been described by many writers as a devastating condition, affecting both the family and the individual's future. As is the case with all pervasive developmental disorder categories, there is considerable controversy about the right treatment for CDD.
Signs and symptoms
A child affected with childhood disintegrative disorder shows normal development and he/she acquires "normal development of age-appropriate verbal and nonverbal communication, social relationships, motor, play and self-care skills" comparable to other children of the same age. However, from between the age of 2 through the age of 10, skills acquired are lost almost completely in at least two of the following six functional areas:
- Expressive language skills (being able to produce speech and communicate a message)
- Receptive language skills (comprehension of language - listening and understanding what is communicated)
- Social skills and self care skills
- Control over bowel and bladder
- Play skills
- Motor skills
Lack of normal function or impairment also occurs in at least two of the following three areas:
In her book, Thinking in Pictures, Temple Grandin argues that compared to "Kanner's classic autism" and to Asperger syndrome, CDD is characterized with more severe sensory processing disorder but less severe cognitive problems. She also argues that compared to most persons with autism, persons with CDD have more severe speech pathology and they usually do not respond well to stimulants.
All of the causes of childhood disintegrative disorder are still unknown. Sometimes CDD surfaces abruptly within days or weeks, while in other cases it develops over a longer period of time. A Mayo Clinic report indicates: "Comprehensive medical and neurological examinations in children diagnosed with childhood disintegrative disorder seldom uncover an underlying medical or neurological cause. Although the occurrence of epilepsy is higher in children with childhood disintegrative disorder, experts don't know whether epilepsy plays a role in causing the disorder."
CDD, especially in cases of later age of onset, has also been associated with certain other conditions, particularly the following:
- Lipid storage diseases (eg Niemann-Pick disease): In this condition, a toxic buildup of excess fats (lipids) takes place in the brain and nervous system.
- Subacute sclerosing panencephalitis: Chronic infection of the brain by a form of the measles virus causes subacute sclerosing panencephalitis. This condition leads to brain inflammation and the death of nerve cells.
- Tuberous sclerosis (TSC): TSC is a genetic disorder. In this disorder, tumors may grow in the brain and other vital organs like kidneys, heart, eyes, lungs, and skin. In this condition, noncancerous (benign) tumors, hamartomas, grow in the brain.
- Adrenoleukodystrophy: In this condition, the myelin that insulates the brain and spinal cord, which transmits information in the nervous system, fades off causing rapid and severe mental and physical deterioaration until vegetative state and/or death occurs.
- Metachromatic leukodystrophy: In this condition, dangerous amounts of lipids build up destroying the myelin sheath that covers the Central and Peripheral Nervous Systems. As a result, a rapid progressive deterioration of the nervous system structure occurs leading to progressive regression of functioning in most if not all areas.
|This section does not cite any references or sources. (February 2013)|
Loss of language and skills related to social interaction and self-care are serious. The affected children face ongoing disabilities in certain areas and require long term care. Treatment of CDD involves both behavior therapy, environmental therapy and medications.
- Behavior therapy: The main aim of Applied Behavior Analysis (ABA) is to systematically teach the child to relearn language, self-care and social skills. The treatment programs designed in this respect "use a system of rewards to reinforce desirable behaviors and discourage problem behavior." ABA programs may be designed by a board-certified specialist in behavior analysis called a "BCBA" (Board Certified Behavior Analyst), but ABA is also widely used by a number of other health care personnel from different fields like psychologists, speech therapists, physical therapists and occupational therapists with differing levels of expertise. Parents, teachers and caregivers are instructed to use these behavior therapy methods at all times.
- Environmental Therapy: Sensory Enrichment Therapy uses enrichment of the sensory experience to improve symptoms in autism, many of which are common to CDD.
- Medications: There are no medications available to directly treat CDD. Antipsychotic medications are used to treat severe behavior problems like aggressive stance and repetitive behavior patterns. Anticonvulsant medications are used to control seizures.
- McPartland J, Volkmar FR (2012). "Autism and related disorders". Handb Clin Neurol 106: 407–18. doi:10.1016/B978-0-444-52002-9.00023-1. PMID 22608634.
- Venkat A, Jauch E, Russell WS, Crist CR, Farrell R (August 2012). "Care of the patient with an autism spectrum disorder by the general physician". Postgrad Med J 88 (1042): 472–81. doi:10.1136/postgradmedj-2011-130727. PMID 22427366.
- Mouridsen SE (June 2003). "Childhood disintegrative disorder". Brain Dev. 25 (4): 225–8. doi:10.1016/s0387-7604(02)00228-0. PMID 12767450.
- Rogers SJ (2004). "Developmental regression in autism spectrum disorders". Ment Retard Dev Disabil Res Rev 10 (2): 139–43. doi:10.1002/mrdd.20027. PMID 15362172.
- Hendry CN (January 2000). "Childhood disintegrative disorder: should it be considered a distinct diagnosis?". Clin Psychol Rev 20 (1): 77–90. doi:10.1016/S0272-7358(98)00094-4. PMID 10660829.
- Malhotra S, Gupta N (December 1999). "Childhood disintegrative disorder". J Autism Dev Disord 29 (6): 491–8. doi:10.1023/A:1022247903401. PMID 10638461.
- Fombone E (June 2002). "Prevalence of childhood disintegrative disorder". Autism 6 (2): 149–57. doi:10.1177/1362361302006002002. PMID 12083281.
- Fombonne E (June 2009). "Epidemiology of pervasive developmental disorders". Pediatr. Res. 65 (6): 591–8. doi:10.1203/PDR.0b013e31819e7203. PMID 19218885.
- Childhood Disintegrative Disorder - Causes
- Malhotra S, Gupta N (1999). "Childhood disintegrative disorder". J Autism Dev Disord 29: 491–8.
- Maurice, Catherine (1993). Let me hear your voice: a family's triumph over autism. New York: Knopf. ISBN 0-679-40863-0. OCLC 26633221.
- Westphal A, Schelinski S, Volkmar F, Pelphrey K (February 2013). "Revisiting regression in autism: Heller's dementia infantilis. Includes a translation of Über Dementia Infantilis". J Autism Dev Disord 43 (2): 265–71. doi:10.1007/s10803-012-1559-z. PMID 22677931.